Down regulation of tumour biomarkers in colon cancer cells with IRNA PFK-1 plus metformin.

Q2 Medicine Journal of Buon Pub Date : 2021-07-01

Eduardo Alejandro Reyes Serratos, Elisa Fernandez Castillo, Lizeth Sanchez Lopez, Mauricio Salinas Santander, Danielle Annette Orozco Nunnelly, Monica Gabriela Sanchez Salazar, Enrique Cervantes Astorga, Ana Maria Rivas Estilla, Clara Patricia Rios Ibarra

{"title":"Down regulation of tumour biomarkers in colon cancer cells with IRNA PFK-1 plus metformin.","authors":"Eduardo Alejandro Reyes Serratos, Elisa Fernandez Castillo, Lizeth Sanchez Lopez, Mauricio Salinas Santander, Danielle Annette Orozco Nunnelly, Monica Gabriela Sanchez Salazar, Enrique Cervantes Astorga, Ana Maria Rivas Estilla, Clara Patricia Rios Ibarra","doi":"","DOIUrl":null,"url":null,"abstract":"Purpose: Metformin has been widely used for the treatment of Type 2 Diabetes Mellitus (T2DM), hyperglycemia and polycystic ovarian syndrome. Recent studies have suggested the potential of this substance as a cancer chemopreventive agent. We evaluated the antitumoral effect of iRNA-PFK-1 and the combined therapy iRNA-PFK-1 + metformin in RKO p53-positive cells.Methods: mRNA levels of tumor suppressor genes AMPK, APC, and c-MYC, KRAS oncogenes were measured by qRT-PCR in RKO cells treated with 25 µM metformin alone or combined with iRNA-PFK-1, to evaluate the effect of both treatments.Results: At 72 h after treatment with either 25 µM metformin, 150 nM iRNA-PFK-1, or the combined treatment, the transcriptional levels of these biomarkers were decreased by ~73% (p˂0.05), ~99.9%, (p˂0.01), and ~76% (p˂0.05), respectively.Conclusion: These in vitro results support the potential therapeutic role of metformin and PFK-1 in the treatment of colon cancer via down-modulation of the expression of several important cancer biomarkers.","PeriodicalId":50248,"journal":{"name":"Journal of Buon","volume":" ","pages":"1210-1218"},"PeriodicalIF":0.0000,"publicationDate":"2021-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Buon","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Metformin has been widely used for the treatment of Type 2 Diabetes Mellitus (T2DM), hyperglycemia and polycystic ovarian syndrome. Recent studies have suggested the potential of this substance as a cancer chemopreventive agent. We evaluated the antitumoral effect of iRNA-PFK-1 and the combined therapy iRNA-PFK-1 + metformin in RKO p53-positive cells.

Methods: mRNA levels of tumor suppressor genes AMPK, APC, and c-MYC, KRAS oncogenes were measured by qRT-PCR in RKO cells treated with 25 µM metformin alone or combined with iRNA-PFK-1, to evaluate the effect of both treatments.

Results: At 72 h after treatment with either 25 µM metformin, 150 nM iRNA-PFK-1, or the combined treatment, the transcriptional levels of these biomarkers were decreased by ~73% (p˂0.05), ~99.9%, (p˂0.01), and ~76% (p˂0.05), respectively.

Conclusion: These in vitro results support the potential therapeutic role of metformin and PFK-1 in the treatment of colon cancer via down-modulation of the expression of several important cancer biomarkers.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

IRNA PFK-1加二甲双胍对结肠癌细胞肿瘤生物标志物的下调

目的:二甲双胍已被广泛用于治疗2型糖尿病(T2DM)、高血糖和多囊卵巢综合征。最近的研究表明，这种物质可能是一种癌症化学预防剂。我们在RKO p53阳性细胞中评估了iRNA-PFK-1和iRNA-PFK-1 +二甲双胍联合治疗的抗肿瘤效果。方法:采用qRT-PCR方法检测25µM二甲双胍单独或联合iRNA-PFK-1治疗的RKO细胞中肿瘤抑制基因AMPK、APC、c-MYC、KRAS癌基因mRNA水平，评价两种治疗的效果。结果:在25µM二甲双胍、150 nM iRNA-PFK-1或联合处理后72 h，这些生物标志物的转录水平分别降低了~73% (p小于0.05)、~99.9%、(p小于0.01)和~76% (p小于0.05)。结论:这些体外实验结果支持二甲双胍和PFK-1通过下调几种重要癌症生物标志物的表达来治疗结肠癌的潜在治疗作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Buon 医学-肿瘤学

自引率

0.00%

发文量

审稿时长

4-8 weeks

期刊介绍： JBUON aims at the rapid diffusion of scientific knowledge in Oncology. Its character is multidisciplinary, therefore all aspects of oncologic activities are welcome including clinical research (medical oncology, radiation oncology, surgical oncology, nursing oncology, psycho-oncology, supportive care), as well as clinically-oriented basic and laboratory research, cancer epidemiology and social and ethical aspects of cancer. Experts of all these disciplines are included in the Editorial Board. With a rapidly increasing body of new discoveries in clinical therapeutics, the molecular mechanisms that contribute to carcinogenesis, advancements in accurate and early diagnosis etc, JBUON offers a free forum for clinicians and basic researchers to make known promptly their achievements around the world. With this aim JBUON accepts a broad spectrum of articles such as editorials, original articles, reviews, special articles, short communications, commentaries, letters to the editor and correspondence among authors and readers. JBUON keeps the characteristics of its former paper print edition and appears as a bimonthly e-published journal with continuous volume, issue and page numbers.